A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
University of Southern California
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
University Hospital, Geneva
University of Nebraska
Emory University
Roswell Park Cancer Institute
Bayer
Albert Einstein College of Medicine
Critical Outcome Technologies Inc.
Masonic Cancer Center, University of Minnesota
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
Amgen
National Cancer Institute (NCI)
NYU Langone Health